Evotec AG and TESARO, Inc. today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology (IO) target. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-tesaro-enter-strategic-partnership-to-discover-novel-immuno-oncology-agents-3